Trial Profile
A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Quetmolimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Eisai Co Ltd
- 08 Nov 2017 Results assessing 52 week safety, pharmacokinetics and safety presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 23 Aug 2017 Status changed from active, no longer recruiting to completed.
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism